KOL Pulse AI
@KolPulseAI
Followers
630
Following
3,529
Media
113
Statuses
1,887
KOL Pulse AI is a Healthcare Intelligence Application focused on the Social Conversations and Digital Signature of Key Opinion Leaders in Medicine.
Savannah, GA
Joined August 2023
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
#EURo2024
• 448996 Tweets
England
• 438688 Tweets
Donald Sutherland
• 284883 Tweets
Spain
• 146702 Tweets
Denmark
• 132545 Tweets
Rice
• 112047 Tweets
Palmer
• 109082 Tweets
Bellingham
• 97319 Tweets
Kane
• 91410 Tweets
Trent
• 84471 Tweets
Falcao
• 83865 Tweets
Foden
• 83719 Tweets
Lamine
• 73728 Tweets
Saka
• 68838 Tweets
Lakers
• 59279 Tweets
Inglaterra
• 57508 Tweets
Kelly
• 56660 Tweets
Nico Williams
• 55980 Tweets
اسبانيا
• 42194 Tweets
Gordon
• 40469 Tweets
#bbcqt
• 39321 Tweets
JJ Redick
• 39033 Tweets
Cucurella
• 36959 Tweets
lorde
• 35684 Tweets
Pedri
• 34797 Tweets
#ESPITA
• 33371 Tweets
Mainoo
• 33006 Tweets
#SpagnaItalia
• 30044 Tweets
Rodri
• 26639 Tweets
Di Lorenzo
• 24102 Tweets
Calafiori
• 23925 Tweets
Morata
• 22685 Tweets
スペイン
• 19744 Tweets
BIENVENIDA FURIA TE AMAMOS
• 18690 Tweets
Kiefer
• 17410 Tweets
Donnarumma
• 16763 Tweets
Fabian Ruiz
• 13017 Tweets
Pinned Tweet
Request a LIVE demo of KOL Pulse AI!
0
0
0
Follow the post progression outcomes update of the controversial FLAURA2 Trial from the
#ELCC24
conference. Key commentary from
@DrJNaidoo
@DrSteveMartin
@StephenVLiu
@dplanchard
#lcsm
👉
0
5
20
Lung Cancer Key Opinion Leaders Gather in Santa Monica at the
#TTLC24
Conference. Social Media Leaders include
@christine_lovly
@NarjustFlorezMD
@chulkimMD
@esinghimd
Follow the top Tweets here:
#LCSM
#iaslc
2
6
14
Myeloma Experts from Top Cancer Centers Express Concerns Re: CARTITUDE-5 trial from
@JanssenUS
👉 tweets from
@ManniMD1
from
@huntsmancancer
,
@AaronGoodman33
from
@UCSDHealth
,
@RahulBanerjeeMD
from
@fredhutch
,
@HiraSMian
from
@McMasterU
#MedTwitter
@BettinaRyll
@AndrewRezvani
0
5
11
Discover the KOL conversations of key clinical trials of cancer therapies
0
3
10
Join the KOL Pulse AI Beta User Group!
1
2
7
PHASE III ALINA Trial data was just published in
@NEJM
. Follow the NSCLC Key Opinion Leader Discussion of the publication, editorial by
@APassaroMD
and
@peters_solange
, as well as the KOL discussion from ALINA data presented at
#ESMO23
by
@bensolomon1
and the discussant
1
2
7
(1/7)KOL Pulse Thread👉 📢
#ASH23
Early Buzz: Global KOL discussions on highly anticipated SYMPATICO trial in mantle cell lymphoma! 🩸 The Phase 3 Trial will be presented by Professor
@michaelwangmd
of the department of Lymphoma & Myeloma
@MDAndersonnews
I am looking forward to presenting this exciting phase 3 data at American Hematology Society (ASH) conference in 2 weeks!
1
3
50
1
2
6
The
@NEJM
just published the results of the KEYNOTE-564 trial by
@merck
. Follow the ongoing KOL Discussions including physicians' praise of researchers
@DrChoueiri
@tompowles1
@TiansterZhang
and criticism of the trial by
@VPrasadMDMPH
@Timothee_MD
@drdgoldstein
and others .
1
2
5
Review the KOL sentiment of the PAPILLON trial, resulting in today's FDA Approval of Rybrevant plus chemo for treatment of NSCLC EGFR Exon 20 insertion mutations 👉KOLs include:
@StephenVLiu
@CharuAggarwalMD
@UrsWeberMD
@DipeshUpretyMD
@Tony_Calles
@RManochakian
@esinghimd
0
4
6
Thread(1/6) Contrasting KOL Views of
#ASH23
Phase 3 PERSEUS trial, comparing Dara-VRd to VRd alone in ASCT-eligible newly-diagnosed multiple myeloma patients. 👉
@Mohty_EBMT
of
@Sorbonne_Univ_
"The findings further support the use of this regimen".
Summary of the PERSEUS trial to be presented at
#ASH23
These results further support the use of this regimen.
(LBA-1 Phase 3 Randomized Study of DARA+VRd Vs Vrd Alone in Pts with NDMM Who Are Eligible for ASCT)
@COMyCongress
@TheIACH
@Mohty_EBMT
1
27
56
1
1
5
@jryckman3
@SuyogCancer
@ASCO
Associated Research is an often overlooked data point in the OpenPayments profile. Perhaps
@ASCO
speakers should share these data as part of their COI discussions
1
1
5
4.
@esinghimd
sharing social media insights for the "online oncologist"
Valid point
@DrSteveMartin
!!
In case you missed our session this morning, TOP 🔟 social media tips for the “online oncologist” are HERE! 👇🏽
#MedTwitter
#lcsm
#TTLC24
@OncoAlert
1
4
21
1
3
5
Key Opinion Leaders criticize the research path of the failed NSCLC CONTACT-01 trial by
@Roche
. Key Commentary by
@EladSharonMD
@TejasPatilMD
@Alfdoc2
@AnisToumeh
#LCSM
#MedTwitter
👉
0
0
4
(9/11)
@VPrasadMDMPH
claimed "No American will ever take gene therapy to lower LDL when you have drugs that do the same. This is such a fucking stupid company and everyone praising it is an idiot" ().
I am so sick of hearing about Verve. No American will ever take gene therapy to lower LDL when you have drugs that do the same. This is such a fucking stupid company and everyone praising it is an idiot.
That is all
@venkmurthy
in contrast is spot on
25
17
320
1
1
4
Key Opinion Leaders react to
@bmsnews
announcement of CHECKMATE 9DW (topline results for the treatment of Advanced Hepatocellular Carcinoma)
#mhcc
#HCC
Top Tweets from
@MarkYarchoan
@SuyogCancer
@GIcancerDoc
@CathyEngMD
@ArndtVogel
👉
0
1
4
Follow the Lung Cancer Discussion of the PACIFIC-2 clinical trial across
#RADONC
, Medical Oncology and Thoracic Surgery KOLs. Key Discussants include
@n8pennell
@JeffBradleyMD
@BrendonStilesMD
@DrewMoghanaki
@Tony_Calles
@jryckman3
@FordePatrick
#elcc24
#LCSM
1
0
3
Follow the Lung Cancer Social Media Buzz from
#TTLC24
Most engaging KOLs include
@chulkimMD
@Latinamd
@NarjustFlorezMD
@LeciaSequist
@StephenVLiu
@BrunaPellini
@COlazagasti
@christine_lovly
#LCSM
0
2
4
Check KOL Conflicts of Interest directly in your X timeline! Get the KOL Pulse Chrome Extension Today!
0
0
3
🧵(1/13)Did any
@fda
ODAC panel members on the recent vote re:"Minimal Residual Disease (MRD)" have potential Financial Conflicts of Interest
#COI
with Pharma and/or Biotech companies?
Let's Check OpenPayments (in order of the Vote Tally below)
FDA ODAC
ODAC approves MRD as surrogate end point for myeloma trials .
12 vs zero . Not a single vote against it . Is the corelation between MRD and OS good enough at trial level to get accelerated approvals ? Will this open gateway for MRD as end point for solid tumors? I hope not.
2
1
7
1
1
3
(8/11) However,
@venkmurthy
tweeted "Results of the heart-1 study of VERVE-101 by $VERV had serious concerning cardiac complications." "May be time to stop trials on this agent for now." He shared his thoughts in a substack post.()
Results of the heart-1 study of VERVE-101 by $VERV had serious concerning cardiac complications.
May be time to stop trials on this agent for now. Here is my thinking:
6
22
78
1
1
3
Follow the Sentiment of Top Physician Key Opinion Leaders in Myeloma regarding the FDA ODAC Vote for MRD as an endpoint for accelerated FDA Approval of Myeloma Therapies.
👉
Interesting Discussions by
@bdermanmd
@VPrasadMDMPH
@oncology_bg
@VincentRK
0
1
3
The FDA Grants Approval to
@ImmunityBio
drug Anktiva based on QUILT-3.032 Clinical Trial.
Follow KOL Sentiments here:
👉
The FDA approved Anktiva (nogapendekin alfa inbakicept-pmln) with (BCG) for BCG-unresponsive non-muscle invasive bladder cancer with
0
0
2
(7/7) Medical journalist Matthew Herper (
@matthewherper
) distilled a simple headline for STAT News "Weight loss drug Wegovy cuts risk of heart attacks in milestone trial,
@elaineywchen
reports. "().
Weight loss drug Wegovy cuts risk of heart attacks in milestone trial,
@elaineywchen
reports.
5
37
142
0
0
1
How much did Pharma influence the recent FDA ODAC vote on MRD as an endpoint for accelerated approval for Myeloma Therapies?
#mmsm
#MedTwitter
#ASCO24
Follow the Key Opinion Leader discussion here
👉
0
1
3
(5/9) Winner of the Hematology and Medical Oncology Fellowship Faculty Teaching Award from
@huntsmancancer
@UofUInternalMed
,
@ManniMD1
Shares his top
#ASH23
abstracts, each with a Teaching Point👉
List of top 10 plasma cell dyscrasia
#ASH23
abstracts.
List may reflect positive/negative studies, but all have influenced thinking.
I will summarize each study with teaching point.
If you are wondering if there are any practice changing myeloma studies- IMO answer is NO.
🧵
6
42
129
1
1
2
Highlights from the
#WinterLung24
conference in Hollywood, FL.
#LCSM
Key Influencers include
@COlazagasti
@Latinamd
@DrSteveMartin
@chulkimMD
@gotoPER
View Top Photos and Slides Here👇
0
1
1
0
0
2
(1/12) KOL Pulse Thread 👉Follow the
@VerveTx
Drama as Biotech Reporter
@adamfeuerstein
targets Nuclear Cardiology Professor and KOL
@venkmurthy
#aha23
. This public argument is against the backdrop of $VERV drastic stock movements in November
#MedTwitter
1
2
2
@esinghimd
@DrSteveMartin
@OncoAlert
@BrendonStilesMD
@StephenVLiu
@NarjustFlorezMD
@DrJNaidoo
@CharuAggarwalMD
@JackWestMD
@maraantonoff
@OncBrothers
@n8pennell
@MDAndersonNews
Follow the Key Opinion Leaders from
#TTLC24
in one List:
#LCSM
0
0
2
Key Opinion Leaders Disagree on Relevance of
@AstraZenecaUS
PHASE II APPLE Trial Update. Should U.S. Oncologists start to consider cost when sequencing drugs for EGFRmut NSCLC? Key Tweets by
@BijoyTelivala
@n8pennell
@StephenVLiu
@NormandBlais
#lcsm
0
0
1
The
@AstraZenecaUS
LAURA trial will be a plenary at
#ASCO24
. KOLs have already been discussing this trial, and some are very interested in the post-progression care of the control arm.
#lcsm
👉
0
0
3
Follow the KOL Discussions of the
#monarchE
Clinical Trial
#bcsm
. KOL Sentiment is trending Negative based on recently published data.
👉
Recent Discussions by
@oncology_bg
@SuyogCancer
@5_utr
Forget laser pointer, you can’t fit 2 molecules of oxygen between these curves!
#monarchE
update.
6
8
41
0
1
2
View Key Insights from
#AHA23
. Top Influencers include
@CMichaelGibson
@drroxmehran
@kaulcsmc
@DrMarthaGulati
0
0
2
(2/8) Dr. Mohit Agarwal (
@MohitAgNeurorad
) congratulates the latest members of
@thecortexclub
, including
@NeuroradLal
,
@sachingujarMD
, and Michelle Miller-Thomas.
#RSNA23
means meeting friends old and new!
Congratulations to the latest
@thecortexclub
members
@NeuroradLal
@sachingujarMD
and Michelle Miller-Thomas!! Welcome to the club and thank you for all your contributions to Neuroradiology education!
4
1
56
2
1
2
@DrYukselUrun
@ASCO
Please visit KOL PULSE for a collection of images captured from tweets at
#GU24
meeting.
0
1
2
Physician Opinion Leaders Accuse American Board of Internal Medicine (ABIM) of Extortion, Propaganda, & Conflict of Interest in Maintaining of Certification Process (MOC). Top Influencers include:
@VincentRK
@AaronGoodman33
@doctorwes
@Dr_AmerZeidan
👇
0
0
0
(2/7) The results made a significant splash. As cardiologist (
@ErinMichos
) put it in a tweet that garnered over 19,000 views, the drug provided a "game changer" benefit.()
Huge news! The
#SELECT
trial presented at
#AHA23
is a game changer. Among adults with CVD and overweight/
#obesity
but without diabetes,
#semaglutide
2.4mg/wk reduced MACE by 20%, HF by 18%, and all-cause mortality by 19%! 👏👏👏
13
198
556
1
1
2
Follow the ongoing social media discussion of the ABIM MOC Controversy by Digital Opinion Leader Physicians. New Discussions by
@AaronGoodman33
@DrJJJavier
@JamesBarnesMD
0
0
0
Top Tweets from
#TTLC24
1.
@AlexSpiraMDPhD
presentation on science Behind KRAS inhibition combinations
Dr.
@AlexSpiraMDPhD
at
#TTLC24
discusses the science behind
#KRAS
inhibitor combinations and why they may be necessary in NSCLC.
0
7
20
1
0
0
Top influencers from
#croi2024
include
@CarlosdelRio7
@MonicaGandhi9
@PaulSaxMD
@AadiaMd
@drlaurajwaters
@LizHighleyman
View the Top Tweets Here:
#HIV
0
0
0
Key Opinion Leaders React to
@GuardantHealth
Colon Screening test: 👉
KOLs include:
@pashtoonkasi
@agrothey
@aparna1024
@DrYukselUrun
@DrSteveMartin
@DrHarryThomas
@professor_gene
#MedTwitter
0
1
0
(3/7) Heme/Onc
@jeff_sharman
Director of Research
@TheUSONetwork
generated KOL discussion about Sympatico with his commentary👉 "A lot of implications from this MCL late breaking abstract!" 👉"New SOC in eligible patients?"
A lot of implications from this MCL late breaking abstract!
1) Ibrutinib approval previously withdrawn in MCL? Time to revisit?
2) Does this combo data impact choice of BTK in r/r MCL?
3) New SOC in eligible patients?
4) Are age related toxicities the same in CLL/MCL?
5
11
43
2
0
1
0
0
1
(7/9) Hematopathologist/Molecular Pathologist
@sanamloghavi
, Director of ECOG-ACRIN Leukemia Bank from
@mdandersonnews
highlights her list of abstracts 👉
#ASH23
abstracts R out
I wanted to highlight a few of ours/our collaborators’, in case U’re spending 2day
#ASHing
with Ur Sunday AM ☕️ 🧵
1. WT1 mut AML
Oral, AML 613
Lead by
@HimaglobinA
J. DiGennaro, in collaboration w/
@Ramikomrokji
C. DiNardo et al
2
14
81
1
0
1
6. Presentation by Dr. Carl Gay on Bispecifics, Trispecifics, and CARTs
Great talk (as always) by Dr Carl Gay
@MDAndersonNews
@IASLC
#TTLC24
on Bispecifics, Trispecifics, and CARTs. These surface targeting approaches are potential game-changers in
#SCLC
0
9
43
1
0
1
(1/5)
#GU24
Real Talk from KOLs 🧵
RE: AMBASSADOR :"..Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO" 👉
@TomPowles
Adjuvant pembro ⬆️ DFS (0.69) but ❌ OS (0.98) in UC, ~10% tox ++. Atezo also had ❌ OS. Nivo had 0.7 DFS but no OS data after ++ years-assuming it’s +ve seems unwise. Without OS we’re over treating. Adjuvant IO in all comers is on shaky ground without more data IMO
#GU24
8
119
278
1
0
1
Follow the BUZZ from
#ELCC24
Lung Concer Meeting of Experts! Physician Social Influencers include
@StephenVLiu
@Tony_Calles
@SuyogCancer
@CharuAggarwalMD
@JordiRemon
@DrJNaidoo
. Full collection of KOL Tweets and Shared Media👉👉
#LCSM
0
0
1
Follow the ROBUST KOL Discussion and discover the Key Data Slides from the FDA ODAC Meeting on Carvykti (Cilta-Cel), CARTITUDE-4 data set, for Multiple Myeloma. Key Discussion points by
@RahulBanerjeeMD
@bdermanmd
@HadidiSamer
@JanakiramMurali
@CraigEmmittCole
#mmsm
#CART
0
1
0
(4/9) Myeloma Expert ,
@rahulbanerjeemd
,Asst Professor
@UWMedicine
@fredhutch
, shares his top abstracts👉
1
0
1
NAPOLI3 and FDA Approval: Is NALIRIFOX the new Standard of care for Metastatic Pancreatic Cancer? Opinion leaders disagree on significance of NAPOLI3 data Key Tweets by
@PamelaKunzMD
@SuyogCancer
@BijoyTelivala
@pashtoonkasi
0
0
1
KOLs Praise the presentation of the AMBASSADOR Trial by
@apolo_andrea
at
#GU24
Top tweets by
@jgong15
@alantanmd
@drchoueri
@siadaneshmand
0
0
1
Physician KOLs React to Research Fraud at
@DanaFarber
cc:
@addictedtoigno1
Key quotes by
@VPrasadMDMPH
@BradBanko
@weldeiry
@davidemccune
@FearLoathingBTX
@realdocspeaks
@renohemonc
@Maratosflier
0
1
1
Comparing notes on our plan to overtake
@ASH_hematology
as top influencers of
#ASH23
😉
Cc
@majorajay
7
3
60
1
0
1
0
0
1
(4/13) Dr. Neil Vasan:
General Payments: Over $26K cumulatively from Novartis, Genzyme, Gilead, etc...
Associated Research: $65K all from Gilead
1
0
0
CONTACT-02 Trial by $EXEL Generates Ethical Concerns by KOL Community
#GU24
. Interesting tweets by:
@matthew_hobbs
@SuyogCancer
@docpook
@Dav_Lorente
@SFreedlandMD
0
2
1
(2/9) From
@Yale
,
@Dr_AmerZeidan
, Associate Prof, Director
#Leukemia
Prog; A/Director Heme CTO & early therapy research, shares his top abstracts to prep you for
#ASH23
👉
Now that
@ASH_hematology
Annual Meeting
#ASH2023
abstracts are out, What presentations are you looking forward to the most & why? I will be sharing my selections for
#ZeidanMDSsm
&
#ZeidanAMLsm
top 10 abstracts for each of
#MDSsm
&
#AMLsm
next week
2
1
33
1
0
1
LAURA Trial from
@AstraZeneca
: New Standard of Care in EGFRmut Lung Cancer or Scientific Colonialism? Follow the Lung Cancer Key Opinion Leader Debate:
@jryckman3
@VamsiVelcheti
@StephenVLiu
@n8pennell
@Garth_Nicholas1
@ClaudioVladmir
#lcsm
#egfr
0
0
1
(5/6) However, Dr Vinay Prasad
@VPrasadMDMPH
, professor
@ucsf
, raises an important point: "More active drugs will always improve PFS. Whether you can get the same OS and better QoL from sequencing is forever unknown."
More active drugs will always improve PFS. Whether you can get the same OS and better QoL from sequencing is forever unknown. Myeloma has failed as a field to answer the question. Discussed here
0
2
14
1
0
0
Follow the Key Opinion Leaders as they discuss the recently updated FDA approval for Carvykti (cilta cel)in Multiple Myeloma. Key Comments (and some tweetorials) by
@ManniMD1
@HadidiSamer
@Abdallah81MD
@bdermanmd
#mmsm
#medTwitter
👉
0
0
1
(6/7) UK Medical account GoggleDocs (
@GoggleDocs
) methodically ticked through the statistically significant benefits behind the buzz ().
‼️SELECT trial - Semaglutide 2.4mg in those with obesity/overweight 🚫diabetes‼️
#AHA2023
🔹Inclusion: >45yrs, BMI >27, eASCVD (stroke/MI/symptomatic PAD)
🔸mean age 61.6, BMI 33.3, 72% male
🔹PEP : 3P MACE - achieved!
HR 0.80, p<0.001
🔸Just missed CV mortality p0.07…
3
52
122
1
0
1
(12/14) Negative😠:Dr. Venk Murthy,
@venkmurthy
, Cardiologist, Nuclear Cardiology Specialist, Professor
@UMich
,👉
"Results of the heart-1 study of VERVE-101 by $VERV had serious concerning cardiac complications."
Results of the heart-1 study of VERVE-101 by $VERV had serious concerning cardiac complications.
May be time to stop trials on this agent for now. Here is my thinking:
6
22
78
1
0
1
Digital Opinion Leaders mock and criticize the
@kisqali_us
#NATALEE
clinical trial:
#bcsm
#medtwitter
1
1
1
Tweet
#5
@JayDShahMD
We learned that PCI can relieve symptoms in appropriately selected patient and ORBITA-2 is really the best “proof” we have to date- I’m not sure it informs practice significantly because we should still use anti-anginal medicines and practice shared decision making with patient.
1
0
3
1
0
1
Artificial Intelligence Trial, S1314-COXEN, by
@FaltasLab
Impressed Key Opinion Leaders at
#GU24
. Key Quotes by
@nataliagandur
@shilpaonc
@jgong15
@TomFlaigMD
and discussant
@MaxKates
0
0
1
0
4
19
1
0
1
6/Cardiologist and Professor
@umichmedicine
,
@venkmurthy
, reminded his colleagues to exercise caution with gene editing therapies as well, "The same sentiment should apply for gene editing in vivo for targets like PCSK9!"
The same sentiment should apply for gene editing in vivo for targets like PCSK9!
Let's see how editing performs for conditions which are more severe than HeFH and where there are fewer alternative treatments
0
3
9
1
0
1
Prepare for
#ASCO24
! Review Key Opinion Leader SoMe comments and sentiment of Top Clinical Trials of 2023-2024. Follow what the leaders in oncology have been sharing!
👉
0
1
1
Tweet
#6
One more note on this - some have pointed out that ORBITA2 is interesting mechanistically even if not directly clinically relevant. But was there much doubt that epicardial artery narrowing was one mechanism for chest pain?
0
0
2
1
0
1
@toddscarbrough
@jryckman3
@n8pennell
@JeffBradleyMD
@BrendonStilesMD
@DrewMoghanaki
@Tony_Calles
@FordePatrick
The physician titles are from the OPENPayments database by CMS:
0
0
1
Key Opinion Leaders react to FDA Approval of
@DayOneBio
OJEMDA (tovorafenib) for relapsed or refractory pediatric low-grade glioma with BRAF fusion,rearrangement, BRAF V600 mutation (Based on FIREFLY-1 clinical trial)
👉
#ASCO24
#MEDTwitter
0
0
1
Follow the Key Opinion Leader discussions of $IPSEY new FDA approval of Onividye for metastatic pancreatic cancer
0
0
0
5.
@StephenVLiu
selfie at the Fairmont Tree
1
0
1
Get KOL Pulse AI Updates to your inbox during
#ASCO24
! Find out what KOLs are saying about key clinical trials. Sign up today!
0
1
2
0
0
1
(7/8)Cyrus A. Raji, MD, PhD (
@cyrus_raji
) shares a CNN summary of his team's work,
@MIRimaging
, linking belly fat to brain inflammation and dementia. He highlighted the PR collaboration with
@RSNA
and the accomplishments of lead author
@MahsaDolatshah1
.
A nice summary by
@CNN
of our press release with
@RSNA
from work done
@MIRimaging
with lead author
@MahsaDolatshah1
(so very proud of you!!!) and our colleagues
@frahmanimd
@tlsmit1
:
4
6
45
2
0
1
(11/14) Negative:😠 Vinay Prasad MD MPH,
@VPrasadMDMPH
,Digital KOL and professor
@ucsf
, 👉"I am so sick of hearing about Verve. No American will ever take gene therapy to lower LDL when you have drugs that do the same."
I am so sick of hearing about Verve. No American will ever take gene therapy to lower LDL when you have drugs that do the same. This is such a fucking stupid company and everyone praising it is an idiot.
That is all
@venkmurthy
in contrast is spot on
25
17
320
1
0
1
Great post from
@OncBrothers
heading into SABCS! Was fortunate to meet up prior to the conference to discuss an exciting week ahead :) Thank you to
@OncLive
for setting this up.
0
3
13
1
0
1
(6/8)Grace G. Zhu, MD (
@totallyskates
) reflects on the importance of mentorship and explores
@SusannaLeeRad
's insights on the subject, reminiscing about the key mentors in her life.
Checking out what
@SusannaLeeRad
has to say about mentorship, an incredibly important relationship. Reflecting on the key mentors in my life…🥰
#RSNA2023
0
3
21
1
0
1
(4/5)RE: BRCAAway "Why only a few patients were hispanic/latino?.."👉
@SoaresAndrey
BRCAAway trial. Why only a few patients were hispanic/latino? Low access do clinical trials and different incidence of HRR in this population as showed by
@raymanneh
. It highlight the importance of run more trials in
#LATAM
@BourlonMaite
@neerajaiims
#ASCOGU24
@ASCO
1
3
13
1
0
1
@jryckman3
@n8pennell
@JeffBradleyMD
@BrendonStilesMD
@DrewMoghanaki
@Tony_Calles
@FordePatrick
In the context of the discussion, it seemed that “outdated radiotherapy techniques” referred to PACIFIC-2. Please clarify if this was not the right interpretation and we’ll update the sentiment accordingly.
1
0
0
What is happening with
@ABIMcert
MOC? Follow the ongoing discussion featuring
@AaronGoodman33
@VincentRK
@doctorwes
@Dr_AmerZeidan
#medtwitter
#asco
👉
0
0
1